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Abstract: A more comprehensive understanding of the human ageing process is required to help
mitigate the increasing burden of age-related morbidities in a rapidly growing global demographic
of elderly individuals. One exciting novel strategy that has emerged to intervene involves the use
of extracellular vesicles to engender tissue regeneration. Specifically, this employs their molecular
payloads to confer changes in the epigenetic landscape of ageing cells and ameliorate the loss of
functional capacity. Understanding the biology of extracellular vesicles and the specific roles they play
during normative ageing will allow for the development of novel cell-free therapeutic interventions.
Hence, the purpose of this review is to summarise the current understanding of the mechanisms that
drive ageing, critically explore how extracellular vesicles affect ageing processes and discuss their
therapeutic potential to mitigate the effects of age-associated morbidities and improve the human
health span.
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1. Introduction
There is a growing number of aged individuals in the global population. It is estimated that within
the next few years, people aged 65 and older will outnumber children below the age of 5 for the first
time in our history [1]. It is predicted that this demographic shift will inevitably be accompanied by a
significant increase in the incidence of age-associated morbidities, including cardiovascular disease,
chronic kidney disease, diabetes, neurodegeneration, osteoarthritis, osteoporosis, and cancer, among
many others. Consequently, this rise of age-related disorders will financially burden health care and
social security systems around the world. The global economic burden of health care is estimated
at €35 trillion over the next two decades, accounting for 15% of the costs of social security systems
and for 20% of the costs of health care systems in the European Union (EU) [2]. There is, thus, a vital
need to improve our understanding of the mechanisms underpinning ageing processes and to develop
novel therapeutic strategies in order to mitigate the effects of age-related morbidities. The upshot will
be an improvement in health span (i.e., more years of healthy living) and a reduction in age-related
co-morbid conditions.
2. Ageing
Ageing, either at the organismal or cellular level, can be defined by the loss of physiological
function over time (Figure 1). Ageing is not a passive process [3] but one actively regulated by
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distinct molecular pathways, layered below a loss of functional physiological capacity and correlated
with frailty and increased likelihood of death. The underpinning mechanisms are considered to be
evolutionarily conserved across taxa [4,5] and reflected in nine distinct hallmarks [6]. These comprise
genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, deregulated
nutrient sensing, mitochondrial dysfunction, senescence, stem cell exhaustion, and altered intercellular
communication [6]. These features mirror the acquisition of allostatic load, which reflects the wear and
tear on the organism, and eventual allostatic overload [7], correlated with dysregulated physiological
function with ageing [8–12]. Consequently, they reflect the accumulation of cell and tissue damage,
the loss of repair capacity, and an increased probability of neo-oncogenesis due to dysregulated cell
proliferation [13–15].
Cells 2018, 7, x 2 of 15 
 
molecular pathways, layered below a loss of functional physiological capacity and correlated with 
frailty nd increased likelihood of death. The underpinning mechanisms are considered to be 
evolutio aril  co ser e  acr s  ta  [4,5] a  refl ct  i  i e isti ct all ar s [6]. These co prise 
geno ic instability, t l ere rte i g, e igenetic alterations, loss of r t stasis, deregulated 
nutrie t sensing, mitochondrial dysfunction, s escence, stem cell exhaustion, and altered 
intercellular c mmunication [6]. These fea ures mirror the acquisition f allostatic load, w ich reflects 
the wear and te r on the organism, and eventual allostatic overload [7], correlated with dysregulated 
physiological function with agei g [8–12]. Consequently, they reflect the ac umulation of cell and 
tissue damage, the loss of repair capacity, and an increased pr bability of neo-oncogenesis due to 
dysregulated cell proliferation [13–15]. 
 
Figure 1. Schematic representation of different trajectories of ageing. The green line indicates a good 
trajectory for normative ageing. The red line indicates a poorer ageing trajectory, associated with a 
steeper decline in age-related physiological functional capacity. Loss of functional capacity results in 
fitness decline, frailty, and a greater risk of mortality. Improving the human health span would 
require interventions that are capable of pushing the poorer trajectory of ageing up and to the right, 
providing more years of good health and vitality. 
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Figure 1. Schematic representation of different trajectories of ageing. The green line indicates a good
trajectory for normative ageing. The red line indicates a poorer ageing trajectory, associated with a
steeper decline in age-related physiological functional capacity. Loss of functional capacity results in
fitness decline, frailty, and a greater risk of mortality. Improving the human health span would require
interventions that are capable of pushing the poorer trajectory of ageing up and to the right, providing
more years of good health and vitality.
2.1. Ageing is Highly Heterogeneous
It is important to recognise that not all individuals age at the same rate or in the same way [16].
Indeed, individual organ systems, cells, organelles, and molecules within individuals may age at
significantly different rates [2]. In order to explain the inter-individual and intra-individual variations
observed during normative ageing, we need to further understand how extrinsic factors, including
environmental, physical, psychological, and socioeconomic factors, interplay with intrinsic elements,
such as genetics and epigenetics. These factors may act synergistically, independently, or cumulatively.
How they do so is still the focus of ongoing research. Recent studies focusing on the epigenetics of
human ageing and how epigenetic changes can significantly impact the way we age [17–21] have
provided novel insight into a series of epigenetic modifications that influence the functional decline
that is associated with organismal ageing [22–26]. However, exacly how these epigenetic changes are
influenced by extrinsic factors among different individuals and different organ systems has not yet
been deter ined. Thus, age-related orbidities and their relationship with psychosocial, nutritional,
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and lifestyle factors, as well as with genetic and epigenetic determinants of ageing, remain to be
elucidated [17,27].
In this respect, the study of animals and how they mitigate some of the loss of physiological
function, common to ageing and diseases of ageing in humans, may be of benefit. Interestingly,
almost all of the diseases that affect humans have an equivalent in the animal kingdom [28]. Hence,
the success of such an approach depends on a study of biomimicry as opposed to simply comparative
biology. For instance, studying the long-lived naked mole rats (Heterocephalus glaber) and how they are
protected from oxidative stress and cancer, could assist in the development of strategies that prevent
or slow down premature ageing. Additionally, the study of rougheye rockfish (Sebastes aleutianus)
and bowhead whale (Balaena mysticetus), which both have documented lifespans of >200 years, could
potentially enhance our understanding of autonomous and non-autonomous cellular senescence
during ageing [28].
Despite advances in geroscience, which have allowed us to better understand how we age, there
is still a pressing need to better understand the mechanisms that drive ageing throughout the life
course and not just in the latter half of life.
2.2. Anti-Ageing Strategies
A number of strategies appear capable of mitigating against the effects of age-related morbidities,
with lifestyle factors such as nutrition, exercise, and other psychosocial factors impacting positively
on health and ageing [29]. The transplantation of organs and tissues can also improve outcomes for
patients with age-associated organ failure. Moreover, while stem cell-based therapies hold significant
promise, a number of hurdles remain to be overcome before they can be of common clinical useage.
These include issues concerning safety, cancer risk, proper cell selection and differentiation, delivery to
the target site, cost, and scalability [30]. Therefore, cell-free therapeutics capable of activating a repair
process would be a suitable alternative to stem cell transplantation.
One novel approach that has been developed recently exploits the use of extracellular vesicle
biology. Alterations in intercellular communication have already been identified as one of the hallmarks
of ageing [6] and extracellular vesicles act as paracrine mediators of such intercellular communication.
However, their role remains largely unexplored in the context of ageing, and this review aims to
discuss recent advances in the field. Interestingly, extracellular vesicles have been associated both
with physiological and pathological ageing and thus offer significant diagnostic potential [7,31].
Additionally, the potential of stem cell-derived extracellular vesicles has also been explored as a novel
regenerative strategy to combat age-related diseases [32]. Indeed, extracellular vesicles offer a cell-free
therapeutic alternative to stem cell transplantation, avoiding the associated risks. Consequently,
the study of extracellular vesicles may prove helpful in obtaining a more comprehensive picture of
ageing processes, mitigating any associated adverse effects on health span and understanding the
mechanisms underpinning the spread of allostatic load across the human body.
3. Extracellular Vesicles
A component of physiological homeostasis has been attributed to the action of extracellular
vesicles, which have proven roles in tissue maintenance and repair [32]. Extracellular vesicles comprise
of all membranous vesicles that are secreted by cells and that encapsulate bioactive molecules, such
as proteins and nucleic acids [32]. These vesicles have been recognised as important mediators of
cell-to-cell communication, both in physiological and pathological states [31]. Extracellular vesicles can
be secreted from almost all cell types and are found in most human biological fluids, including
plasma, urine, synovial fluid, and bronchial lavage fluid [33,34]. They are capable of affecting
the phenotype of recipient cells, after local or systemic circulation, by intercellular transfer of their
molecular payloads [35,36]. Their bioactive cargo can include double-stranded DNA [37], mRNA,
micro-RNAs (miRNAs) and other non-coding RNAs [37–40]. We have previously proposed at least
three mechanisms of action (Figure 2) through which the extracellular vesicles can alter the phenotype
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of recipient cells [32]. Firstly, through the translation of extravesicular mRNAs. Once extracellular
vesicle endocytosis has taken place and the mRNAs of extracellular vesicle origin have been released
within the recipient cell cytoplasm, their translation can take place. The translated proteins can then
directly affect the phenotype of the cell. Secondly, through miRNA-mediated regulation of the host cell
mRNAs at the post-transcriptional level. Thirdly, through direct extravesicular protein action within
the recipient cells [32]. Transfer of these biologically active cargoes can generate functional changes
directly in recipient cells and alter their epigenetic landscape. These may also provide a molecular
basis for the effects of non-cell autonomous senescence and the spread of allostatic load across the
body [7,38].
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Figure 2. Extracellular vesicle mechanisms of action. Extracellular vesicles can confer functional
changes and alter the phenotype of recipient cells through the action of their molecular payload.
This involves: 1. extracellular vesicle mRNA translation within the recipient cell cytoplasm, 2.
regulation of gene expression mediated by extravesicular miRNA, and 3. direct extracellular vesicle
protein action.
3.1. Microvesicles and Exosomes
The majority of previous research has focused on two distinct classes of extracellular vesicles:
exosomes and microvesicles. Exosomes have a size range of 30–100 nm diameter and are released
via multi-vesicular endosome fusion with the plasma membrane [41–45]. Microvesicles are bigger
than exosomes, ranging in size from 100 to 1000 nm, and are shed directly from the plasma
membrane [43,45]. Apart from differences in size and point of origin, these two broad classes of
vesicles can be distinguished by their membrane proteins and RNA markers [46]. For instance,
exosomes are positive for CD9 marker expression, while microvesicles do not express CD9 on their
surface. Moreover, the CD40 membrane protein is present only on microvesicles and not exosomes [47].
3.2. Isolation Methodology
Extracellular vesicles can be isolated from the cell culture media of numerous cell types or from
body fluids primarily via centrifugation and ultrafiltration, while other isolation techniques have been
critically reviewed elsewhere [48,49]. Brief mention of methodology is important, as centrifugation,
while enabling isolation of the correct size class of vesicles, often results in trappage of other vesicle
types [50,51]. Ultrafiltration, combined with characterisation of vesicle membrane proteins, is required
to subsequently guarantee successful purification from other extracellular vesicle contaminants and a
successful vesicle preparation of the desired type. This is critical to ensure and validate the correct
separation between the different size classes of extracellular vesicles in order to study their role in
ageing, as well as their therapeutic potential.
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4. Role of Extracellular Vesicles in Ageing
Extracellular vesicles are a heterogeneous population whose molecular payloads have been
shown to be dependent on the cell type of origin. Most notably, stem cell and cancer cell extracellular
vesicles have been identified to have a distinct composition [52,53]. These findings could allow
for more accurate identification of extracellular vesicle subtypes and pave the way for the use of
extracellular vesicles as biomarkers of diagnostic value. Indeed, extracellular vesicles have recently
been under investigation as possible biomarkers of both cancer and ageing [53–55]. Extracellular
vesicles secreted by cancer cells can provide information on driver mutations, molecular subtypes,
or drug resistance [54], while miRNAs from extracellular vesicles derived from saliva or serum have
shown good association with age [55,56].
4.1. A Double-Edged Sword
Extracellular vesicles have been identified as key mediators of paracrine signaling, both in
physiological and pathological states associated with ageing [57]. They can mediate beneficial
effects, in processes such as wound healing and tissue regeneration, as well as detrimental effects,
such as promoting oncogenesis and cellular senescence [58]. Additionally, extracellular vesicles may
have a range of age-related effects including promotion of oncogenic transformation, resistance to
apotosis, epithelial-to-mesenchymal transition and metastasis, stimulation of angiogenesis, evasion of
immunosurveillance, and resistance to anticancer treatment [40,52,58–63]. These negative properties,
however, can be exploited for therapeutic benefit, as they are also capable of spreading sensitivity to
treatment across a population of cancer cells [52].
Exosomes can mediate the removal of cytotoxins from cells. For instance, as a branch of the
endolysosomal pathway, they can contribute to cellular homeostasis by removing misfolded or
unwanted proteins and cytoplasmic DNA, both of which can be targeted to multivesicular bodies and
released via exocytosis [57,64]. Thus, exosomes potentially play a key role in the age-related loss of
proteostasis [65]. Conversely, microvesicles have been demonstrated to have a direct role in enabling
tissue regeneration by delivering bioactive molecules to target cells [47]. One negative connotation for
exosomes and the miRNAs they contain, is that they may provide a mechanism responsible for the
spread of allostatic load between different tissues and organs across the body, thus modulating the
rate of ageing at a systemic level [7]. Similarly, microvesicles released by cancer cells may facilitate
cancer progression by transferring payloads that stimulate invasion, metastasis, and angiogenesis or
by removing chemotherapeutic drugs from cancerous cells [66].
4.2. Role in Cellular Senescence
Numerous studies have suggested that endogenous or exogenous stress can affect the amount
or content of secreted extracellular vesicles [7,38,58,67]. It has been speculated that this can provide
a communication channel through which cells can send a “distress” signal, enabling other cells to
better prepare or react to the stressful stimulus [58]. While this process can have beneficial effects in
the short term, it can also become maladaptive and constitute one of the paths through which stress
can accelerate the rate of ageing [7]. For instance, senescence is thought to be a protective mechanism
that prevents damaged cells from undergoing malignant transformation. It has also been implicated in
both developmental processes and wound healing [68–70]. Senescent cells release an increased amount
of extracellular vesicles, which may be a non-canonical part of the senescence-associated secretory
phenotype (SASP) [67,71,72]. Through the SASP, senescent cells can spread the senescent phenotype
to neighbouring non-damaged cells via a bystander effect [73]. Given the accumulation of senescent
cells in tissues as part of normative ageing, extracellular vesicles may thus contribute to the creation
of a pro-inflammatory and pro-senescent microenvironment that acts as a significant contributor to
physiological ageing and age-related disease [74]. Indeed, senescence-associated extracellular vesicles
appear to be a novel SASP factor involved in age-associated lung disease. For instance, elevated
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levels of exosomal miR-21 in the serum have been associated with idiopathic pulmonary fibrosis [75].
The exosomal miR-21 might thus play a significant role as a SASP factor. Cellular senescence is a key
area of biogerontology research. The potential therapeutic effect of ablating senescent cells in vivo,
through genetic or pharmacological means, has already been demonstrated in pre-clinical models in
mammals [8,69]. Benefits from the clearance of senescent cells in a number of models have included
protection from cancer, cardiovascular disease, and a lifespan increase of up to 30% [8,9,69,76].
4.3. Role in Genomic Instability
Extracellular vesicles may also play a role in promoting another hallmark of ageing, namely
increasing genomic instability, through the transfer of retrotransposons [77]. Extracellular vesicles
derived from cancer cells have in particular been shown to be highly enriched in retrotransposon
sequences, which they can transfer to recipient cells [77]. Retrotransposons are mobile DNA elements
capable of creating and inserting multiple copies of themselves into the host genome [78]. Indeed,
around half of mammalian genomes are composed of such repetitive sequences [79]. It is worth noting
that the process of retrotransposition involves a double-strand break in the DNA and therefore even an
unsuccessful transposition event (i.e., one that does not end with an insertion of the retrotransposon
sequence) can still be mutagenic [78]. Intriguingly, retrotransposon expression has been found to
increase in senescent cells and may be a driver of ageing [78].
4.4. Role in the Spread of Disease
Extracellular vesicle secretion has also been shown to change with age and disease. For instance,
aged rat mesenchymal stem cells (MSCs) secrete more exosomes than their young counterparts.
However, these vesicles have a lower content of anti-inflammatory miRNAs [52] and thus could
theoretically contribute to the inflammatory burden that comes with age. In a separate study,
MSC microvesicles that originated from older rats were demonstrated to have a lower content of
miR-133b-3p and miR-294, two miRNAs that inhibit TGF-β1-mediated epithelial-to-mesenchymal
transition, which is a process that contributes to renal fibrosis [80]. Thus, microvesicles from aged MSCs
may be less capable of protecting kidneys from fibrosis, which in turn may lead to the development of
chronic kidney disease, a proven disease of accelerated ageing [27].
Extracellular vesicles have also been implicated in the spread of a number of other diseases,
for instance by shuttling toxic protein aggregates or misfolded proteins, including those involved in
Alzheimer’s disease and prion diseases [7,58,60,81]. In addition, increased exosome secretion by the
retinal pigmented epithelium may be a factor contributing to the accumulation of the extracellular
material drusen, which is observed in age-related macular degeneration [58,82]. Exosomes have been
implicated in the transformation of vascular smooth muscle cells (VSMCs), which contributes to
vascular calcification [83]. Exosomes secreted by VSMCs exposed to stressful stimuli promote local
calcification, while blocking exosome secretion prevents calcification [83,84]. Extracellular vesicles
are also able to spread a variety of pathogens including HIV, hepatitis C, and Toxoplasma, among
others [81]. Finally, extracellular vesicles have also been identified to aggravate autoimmune diseases
such as rheumatoid arthritis [81].
Overall, extracellular vesicles have been implicated both in physiological and pathological ageing,
and it is essential that we further comprehend their biology. Additionally, it is important to distinguish
and understand the roles that different extracellular vesicle subclasses play during ageing.
5. Combating Diseases of Ageing with Extracellular Vesicles
Although once thought to be cell debris, there is now solid evidence to indicate that extracellular
vesicles play a vital role in intercellular communication, stem cell regulation, and critically tissue
regeneration [85–88]. Specifically, extracellular vesicles, such as microvesicles and exosomes, isolated
from stem cells or stem cell regulatory cell types, have been revealed to display significant regenerative
properties in a number of cases of age-associated tissue loss of function [32]. Through the transfer of
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bioactive molecules, these extracellular vesicles are capable of conferring therapeutic effects in cases
of cardiac, lung, retinal, neural, pancreatic, and kidney damage, which accompany ageing (Figure 3).
Hence, there is growing interest in exploring extracellular vesicles as therapeutic mediators capable of
conferring beneficial changes in the epigenetic landscape of ageing cells and organs.Cells 2018, 7, x 8 of 15 
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functional capacity in a number of key organs. icrovesicles, derived fro ste cel s or stem cel
regulatory cell types, such as Pathfinder cells, can become a novel cell-free therapeutic interv ntion to
mitigate the undesirable eff cts of ageing by enhancing tissue regeneration and thus improving the
human health span.
5.1. Cardioprotective Effects
Human induced luripotent stem cells (iPSCs) have be n used as a source of microv sicles for
therapeutic pplications. These iPSC-derived microvesicles were able to confer iPSC regenerative
att ibutes to adult somatic cells, through the transfer of their molecular ayloads, co prising a s ries
of RNAs, miRNAs, and p oteins. As a esult, the iPSC-derived microvesicles exerted proliferati e and
protective effect on cardiac MSCs, while al o enhancing their differentiation potential, by impacting
on their transcripto e and proteomic profile. These mic ovesicles were also capable of transferring
exogenous transcripts from genetically modified iPSCs. Hence, future t erapeuti strategies can benefit
from t genetic nhancement of the conte t of extracellular vesicles [89]. These observations were also
confirmed in vivo, wher both microvesicles and exos mes, is lated from iPSCs, were able to transfer
miRNAs to the ischemic myocardium of n acute myocardi l ischemia/reperfusion injury mou
model and protect the cardiomyocytes [90]. Additionally, ex som s of MSC origin wer involved in
the mainten nce of tissue homeostasis, protecting ischemic cardiomyocytes by transmission of miR-22,
leading to reduced apoptosis. The miR-22 anti-apoptotic effect was mediated by direct targeting and
Cells 2018, 7, 110 8 of 15
subsequent downregulation of the methyl CpG binding protein 2, which controls gene expression
through epigenetic regulation [91].
5.2. Treatment of Lung Diseases
Moreover, the therapeutic potential of MSCs and their extracellular vesicles has been investigated
in vitro for the treatment of acute lung injury and acute respiratory distress syndrome- [92–94].
The significance of paracrine factors for the treatment of the above disorders was demonstrated
in an acute lung injury model of rat alveolar epithelial cells through restoration of sodium transport
and preservation of epithelial permeability [95]. MSC-derived exosomes were also able to provide a
protective effect in a model of hypoxia-induced pulmonary hypertension [96]. Similarly, microvesicles
originating from MSCs have been demonstrated to provide significant therapeutic efficacy in the
presence of acute lung injury and acute respiratory distress syndrome in mice [97].
5.3. Regeneration of the Retina
Microvesicles derived from mouse embryonic stem cells have also been explored as a novel
therapeutic intervention for the regeneration of the retina. The microvesicles can transfer RNAs and
miRNAs to Müller cells, inducing pluripotency and allowing them to differentiate into cells of retinal
lineage [98].
5.4. Neural Regeneration
The therapeutic potential of microvesicles and exosomes for the development of interventions
that can treat damage in the nervous system has also been discussed elsewhere [99]. Indeed, there is
strong supporting evidence to suggest that the MSC-based therapies, applied in numerous models
of neurodegenerative disorders, confer regenerative effects via paracrine mechanisms, involving
extracellular vesicles, such as microvesicles and exosomes [100]. Interestingly, miR-133b transfer
by MSC exosomes demonstrates beneficial effects on neural cells in rodent stroke models [101–103].
Furthermore, microvesicles isolated from macrophages have been shown to confer regeneration to
peripheral nerves, stimulate proliferation and migration of Schwann cells, and contribute to axonal
regeneration after nerve injury [104]. However, the potential of extracellular vesicles to transfer toxic
molecules, as may occur in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease,
necessitates that further investigation is required in order to develop safe and effective strategies to
mitigate against neuronal dysfunction [105].
5.5. Treatment of Renal and Pancreatic Damage
In the instance of renal recovery following damage or age-related dysfunction, microvesicles of
MSC origin can be protective following glycerol-induced, ischemia-reperfusion and cisplatin-induced
acute kidney injury. This effect has been particularly attributed to the horizontal transfer of mRNA
and miRNA molecules [106–108]. MSC microvesicles can also reverse acute and chronic kidney
injury through the inhibition of apoptosis and subsequent stimulation of proliferation [109,110].
This is congruent with seminal data derived from the use of Pathfinder cells. These cells,
which are a putative stem cell regulatory cell type, were able to enhance the repair of kidneys and
pancreata in mice, following acute ischemic renal damage and streptozotocin (SZT)-induced diabetes,
respectively [111,112]. This therapeutic effect was determined to be paracrine in nature, involving
the action of microvesicles that were capable of working across a species barrier in a concordant
xenotranspalantation model. Interestingly, only the administration of microvesicles, but not exosomes,
was able to mediate the functional recovery of the pancreas in this model [47]. Critically, these
observations were incongruent with previous observation using exosomes in ischemia models in
mice but may be attributable to exosome preparations in these other models being contaminated with
microvesicles. In support of such an assertion, microvesicles from endothelial progenitor cells have
demonstrated therapeutic potential in the treatment of kidney damage following ischemia-reperfusion
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injury in rats. It has also been suggested that this effect was miRNA-mediated and involved miRNA
delivery to resident renal cells [113].
5.6. Systemic Benefits
Finally, extracellular vesicles have been implicated in mediating the systemic benefits of exercise.
Following exercise, muscle and other tissues increase the release of microvesicles and exosomes into
the circulation, transferring a series of factors, termed exerkines [114]. They include anti-inflamatory
peptides, RNA species, and metabolites, which are responsible for facilitating peripheral organ cross
talk. It has been proposed that extracellular vesicles following exercise or bioengineered extracellular
vesicles that incorporate therapeutic exerkines, could have application in the tratment of obesity, type
2 diabetes melitus, atherosclerosis, and other age-associated metabolic disorders [114,115].
6. Conclusions
Studying the role of extracellular vesicles, in cell-to-cell communication and in the context of
physiological and pathological ageing, will enhance our understanding of the ageing process and
the mechanisms underpinning the spread of allostatic load across the human body. Additionally,
understanding the associated mechanisms of action, during maintenance of organismal homeostasis
and tissue regeneration throughout the life course, could prove beneficial for the development of novel
cell-free therapeutic interventions that could improve the health span and combat age-related loss of
function and diseases.
Extracellular vesicles and specifically microvesicles are in clinical trials or moving into clinical
development on a number of fronts [116]. In comparison to cell-based therapies, this cell-free
regenerative strategy offers a lower risk and potentially higher scalability. Finally, production of
artificial vesicles, which can carry and transfer the required bioactive payload, such as therapeutic
miRNAs, to target cells could be developed as an alternative therapeutic strategy, to facilitate tissue
regeneration and deal with organ loss of function and disease that comes with ageing.
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